TrialSignal transduction and targeted therapy2024

Benmelstobart plus anlotinib in patients with EGFR-positive advanced NSCLC after failure of EGFR TKIs therapy: a phase I/II study.

Meiqi Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.